PubMed Health⌕ Search

Biomedical subjects

R Boniver

Publications and source records attributed to R Boniver.

At least 19 recordsLinked to original sources
PubMed1989

[Evaluation of cetirizine and of terfenadine in the treatment of perennial allergic rhinitis].

Thirty patients suffering from perennial allergic rhinitis took part in a cross-over, double-blind study during which they were treated for 3 two-week periods with either 10 mg cetirizine nocte or 60 mg terfenadine given morning and evening, or with a placebo. Both the active products were found to significantly improve the symptoms when compared to placebo (p less than or equal to 0.001). Cetirizine helped to reduce the symptoms of a blocked nose to a significantly greater extent than terfenadine (p less than or equal to 0.05). A significantly larger number of patients (p less than or equal to 0.05) preferred cetirizine (17/30) to terfenadine (6/30). Four patients taking cetirizine, and six of those taking terfenadine, reported a mild sedative effect.

Adolescent↗
PubMed1979

Vertigo, particularly of vascular origin, treated with flunarizine (R 14 950).

The antivertiginous properties of flunarizine were evaluated in three consecutive studies --- two open and one double-blind --- in an total of 99 patients showing definite vertigo. Dosage was two tablets (= 20 mg) t.i.d. for three days in Study I (50 patients), 20 mg. t.i.d. for two months in study II (31 patients), and weekly decreasing doses of four, three, two and one (maintenance) tablets of flunarizine or placebo for three months in study III (9/18 patients with vertigo of recent origin). Improvement of vertigo was significant both objectively and subjectively in studies I and II. In study III, objective tests were always clearly in favour of flunarizine, but subjectively, flunarizine was superior only by month two. Vertigo of vascular origin seemed to be a preferential indication for flunarizine treatment. No major side-effects were found in these studies.

Adolescent↗
PubMed1978

Vertigo, particularly of vascular origin, treated with flunarizine (R 14 950).

The antivertiginous properties of 1-[bis(p-fluorophenyl)-methyl]-4-cinnamylpiperazine (flunarizine, R 14 950) were evaluated in three consecutive studies -- two open and one double-blind -- in a total of 99 patients showing definite vertigo. Dosage was two tablets (= 20 mg) t.i.d. for three days in Study I (50 patients), 20 mg t.i.d. for two months in Study II (31 patients), and weekly decreasing doses of four, three, two and one (maintenance) tablets of flunarizine or placebo for three months in Study III (9/18 patients with vertigo of recent origin). Improvement of vertigo was significant both objectively and subjectively in Studies I and II. In Study III, objective tests were always clearly in favour of flunarizine, but subjectively, flunarizine was superior only by month two. Vertigo of vascular origin seemed to be a preferential indication for flunarizine treatment. No major side-effects were found in these studies.

Adolescent↗